A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies.
| Image |  |
|---|---|
| Description | scientific article published on June 2015 |
| Author/s |
author: Armand Bensussan |
| Publication date | June 1, 2015 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |